Reflections on the Movement in California to Repeal the State’s Ban on Affirmative Action

VIKRAM DAVID AMAR

Illinois law dean and professor Vikram David Amar offers three observations on a measure recently approved by the California legislature that would, if approved by the voters, repeal Proposition 209, the voter initiative that has prohibited affirmative action by the state and its subdivisions since its passage in 1996. Amar praises the California legislature for seeking to repeal Prop 209 and for seeking to do so using the proper procedures, and he suggests that if Prop 209 is repealed, legal rationales for the use of race should be based not only on the value of diversity (as they have been for some time now), but also on the need to remedy past wrongs against Black Americans.

Read More

B/E Aerospace, Inc. v. C&D Zodiac, Inc

Court: US Court of Appeals for the Federal Circuit

Docket: 19-1935

Opinion Date: June 26, 2020

Judge: Jimmie V. Reyna

Areas of Law: Intellectual Property, Patents

On inter partes review (IPR) of B/E’s patents, the Patent Trial and Appeal Board found certain claims unpatentable as obvious. The patents relate to space-saving technologies for aircraft enclosures such as lavatory enclosures, closets, and galleys. The patents are directed to space-saving modifications to the walls of aircraft enclosures; they are not directed to the structures contained within those walls. The Federal Circuit affirmed, rejecting an argument that the Board incorporated a claim limitation that is not present in the prior art. The challenged claims would have been obvious because modifying a combination of prior art to include a second recess was nothing more than the predictable application of known technology. The Board fully articulated its conclusion of obviousness, and substantial evidence supports the Board’s determination of obviousness independent of whether it erred in considering design drawings.

Electronic Communication Technologies, LLC v. ShoppersChoice.Com, LLC

Court: US Court of Appeals for the Federal Circuit

Docket: 19-2087

Opinion Date: July 1, 2020

Judge: Wallach

Areas of Law: Intellectual Property, Legal Ethics, Patents

ECT sued ShoppersChoice for infringement of its 261 patent, directed “to systems and methods that notify a party of travel status associated with one or more mobile things. ShoppersChoice challenged claim 11 as patent-ineligible, 35 U.S.C. 101. ShoppersChoice moved to join a patent eligibility hearing set in a parallel lawsuit, in which ECT alleged claim 11 infringement against other companies. The court conducted a consolidated hearing and invalidated claim 11 as directed to the abstract idea of providing advance notification of the pickup or delivery of a mobile thing. The Federal Circuit affirmed, holding that “the claim only entails applying longstanding commercial practices using generic computer components and technology.” ShoppersChoice sought attorney fees, citing evidence that ECT sent standardized demand letters and filed repeat infringement actions to obtain low-value “license fees” and force settlements. Before the court ruled, a California District Court awarded attorney fees against ECT in another case related to the patent. The Federal Circuit vacated a holding that the case was not exceptional. A pattern of litigation abuses characterized by the repeated filing of patent infringement actions for the sole purpose of forcing settlements, with no intention of testing the merits of one’s claims, is relevant to a district court’s exceptional case determination. The court clearly erred by failing to consider the objective unreasonableness of ECT’s alleging infringement of claim 11 against ShoppersChoice.

Immunex Corp v. Sandoz Inc.

Court: US Court of Appeals for the Federal Circuit

Docket: 20-1037

Opinion Date: July 1, 2020

Judge: O'Malley

Areas of Law: Drugs & Biotech, Intellectual Property, Patents

The patents at issue are directed to the fusion protein etanercept and methods of making the same. Etanercept is the active ingredient in Immunex’s biologic drug Enbrel®, which is primarily indicated for reducing the signs and symptoms of moderately to severely active rheumatoid arthritis, an autoimmune disorder. Sandoz filed an abbreviated Biologics License Application (aBLA), seeking approval to market Erelzi, a biosimilar version of Enbrel®. In a patent infringement suit under the Biologics Price Competition and Innovation Act, Sandoz stipulated to infringement of the asserted claims of the patents-in-suit. The district court held that Sandoz had failed to prove that the asserted claims of the patents-in-suit were invalid. The Federal Circuit affirmed, rejecting claims of obviousness-type double patenting; failure to meet the written description requirement; and obviousness.